Ametek Inc

Q2 performance was exceptionally strong (beats on growth, margins, and cash): Sales $2.04B (+15% YoY; organic +10%; acquisitions +5 pts); orders $2.3B (+28% YoY; organic +25%); backlog $4.11B (record) with book-to-bill ~1.12 and ~80% of backlog expected to ship in the next 12 months. Operating income $544M (+18%), operating margin 26.6% (+60 bps), core margin 27.1% (+110 bps); free cash flow $452M (+37%) and FCF conversion to net income ~111%. EPS $2.09 (+17%) and above guidance range ($1.96–$2.00).

Demand breadth and end-market “thematics” (surprisingly resilient despite a 2-speed economy narrative): Growth was described as broad-based across all divisions with standout demand in semiconductor-related instrumentation (EIG) and MedTech (notably Paragon Medical within EMG). Management framed growth as tied to mission-critical infrastructure build-outs: AI/semiconductor manufacturing, power grid build-out and energy security, defense modernization, commercial aerospace supercycle, and precision automation—emphasizing durability because customers are making multiyear capital investments and AMETEK supplies engineered, high-switching-cost solutions.

FY 2026 and Q3 outlook raised (clear upward revision): Full-year sales now expected ~+10% (organic mid-to-high single digits, raised with first-half strength). Full-year diluted EPS now $8.20–$8.30 (up ~10–12% vs. last year), increased from prior $7.94–$8.14. Q3: expects high single-digit sales growth and adjusted EPS $2.08–$2.10 (up 10–11% YoY). Management noted some prudence/conservatism in modeling but confidence in delivering the revised guide.